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Age-associated changes in the blood–brain barrier: comparative studies in human and mouse
Aims: While vascular pathology is a common feature
of a range of neurodegenerative diseases, we hypothe-
sized that vascular changes occur in association with
normal ageing. Therefore, we aimed to characterize
age-associated changes in the blood–brain barrier
(BBB) in human and mouse cohorts. Methods:
Immunohistochemistry and Evans blue assays were
used to characterize BBB dysfunction (tight junction
protein expression and serum plasma protein accumu-
lation), vascular pathology (pericyte loss and vascular
density) and glial pathology (astrocyte and microglial
density) in ageing neurological control human pre-
frontal cortex (a total of 23 cases from 5 age groups
representing the spectrum of young adult to old age:
20–30 years, 31–45 years, 46–60 years, 61–75 years
and 75+) and C57BL/6 mice (3 months, 12 months,
18 months and 24 months, n = 5/6 per group).
Results: Quantification of the tight junction protein
ZO-1 within the cortex and cerebellum of the mouse
cohort showed a significant trend to both increased
number (cortex P < 0.001, cerebellum P < 0.001) and
length (cortex P < 0.001, cerebellum P < 0.001) of
junctional breaks associated with increasing age. GFAP
expression significantly correlated with ageing in the
mice (P = 0.037). In the human cohort, assessment of
human protein accumulation (albumin, fibrinogen and
human IgG) demonstrated cells morphologically resem-
bling clasmatodendritic astrocytes, indicative of BBB
dysfunction. Semiquantitative assessment of astrogliosis
in the cortex expression revealed an association with
age (P = 0.003), while no age-associated changes in
microglial pathology, microvascular density or pericyte
coverage were detected. Conclusions: This study
demonstrates BBB dysfunction in normal brain ageing,
both in human and mouse cohorts.
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Introduction
The mechanisms underlying central nervous system
(CNS) dysfunction and cognitive deterioration during
ageing are complex. It is likely, however, that blood–
brain barrier (BBB) dysfunction has a contributory role
in the ageing process. The BBB is formed by a continu-
ous layer of cerebral endothelial cells (CECs) held
together by tight junctions, which limit paracellular
and intramembranous diffusion. This restricts penetra-
tion of molecules into the CNS and provides high elec-
trical resistance [1]. The ‘sealing’ feature of the tight
junctions is due to the unique expression of specific
transmembrane proteins, including occludin and
Correspondence: Julie Simpson, Sheffield Institute for Translational
Neuroscience, 385a Glossop Road, The University of Sheffield,
Sheffield, S10 2HQ, UK. Tel: +44 114 222 2242; Fax: +44 114
222 2290; E-mail: julie.simpson@sheffield.ac.uk
1Joint first authors.
2Joint senior authors.
© 2017 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
1
Neuropathology and Applied Neurobiology (2017) doi: 10.1111/nan.12408
junction adhesion molecules (JAMs) [2,3]. Scaffolding
proteins, such as zonula occludens-1 (ZO-1), link the
tight junction complex to the cytoskeleton [4,5]. As a
result the molecular traffic of endogenous substances,
necessary to maintain CNS homeostasis, occurs mainly
by transcellular means. Transport of small molecules,
such as glucose and amino acids, requires the expres-
sion of specific transporters, whereas larger molecules,
such as peptides, cross the BBB by transcytosis. Other
transporters specific to CECs, such as P-glycoprotein
(also known as multidrug resistance protein 1 or ATP-
binding cassette subfamily B member 1), are specialized
for efflux of a wide range of substrates and contribute
to removal of harmful substances from within the CNS
[6]. The phenotype of CECs is under inductive influence
of perivascular pericytes and the end-feet of astrocytes.
Together, these cells form a functional cellular complex
termed the ‘neurovascular unit’ (NVU), which provides
a coordinated response to maintain CNS homeostasis
and function [6].
Leakage of the BBB, associated with changes in the
expression of tight junction proteins, has been found in
various acute and chronic neurological disorders
[7–11]. However, to date, studies investigating the
effect of normal, physiological ageing on the integrity
of the BBB are conflicting, with some studies conclud-
ing the BBB remains intact [12–16], while others show
evidence of increased permeability [17–19]. A system-
atic review suggests that BBB breakdown may be com-
mon in normal human ageing as evidenced by
increased cerebrospinal fluid/plasma albumin ratios
and brain imaging studies [20]. Indeed, our studies in
an ageing population-representative neuropathology
cohort show that BBB leakage is a common feature of
the cerebral cortex [21] and white matter in the ageing
human brain [22], but these studies were confined to
the elderly population (>65 years).
To further investigate the effects of ageing on NVU
integrity through adult life, we determined BBB perme-
ability in cohorts of mice and an ageing human
autopsy cohort, in addition to microvascular density,
glial pathology and vascular pathology in the human
cohort. Previous studies have shown leakage of serum
proteins, such as albumin, fibrinogen and IgG, to be
robust markers of impaired BBB function [23,24],
therefore we used albumin-binding dyes and immuno-
histochemistry to visualize leakage in mice and human
aged tissues respectively. Our findings provide evidence
of an age-associated decline in BBB function which
may contribute to the vulnerability of the aged CNS to
neurodegenerative disease.
Material and methods
Study cohort: Mouse
C57BL/6 mice were purchased from Charles River at
3 months (young adult), 12 months (adult),
18 months (middle age) and 24 months (old). All mice
were sacrificed and perfused with phosphate-buffered
saline (PBS). The brain and spinal cord were dissected,
then either formalin fixed and paraffin embedded
(FFPE) (n = 5 per group), snap frozen in liquid nitrogen
or used for Evans blue assay (n = 6 per group), as
described below. All animal experiments were con-
ducted following ethical review processes in accordance
with the Animals (Scientific Procedures) Act 1986 of
the UK government and the ARRIVE guidelines [25].
Study cohort: Human
Post mortem human brain tissue was obtained from the
Edinburgh Medical Research Council sudden death
brain bank, who selected the cases and granted
approval for the use of tissue in this study (Edinburgh
Brain Bank REC reference 11/ES/0022). FFPE tissue
was obtained from the prefrontal association cortex
(Brodmann areas 8/9) of cases without a history of
neurological disease selected from five age groups to
cover the spectrum of young adult to old age, namely
20–30 years, 31–45 years, 46–60 years, 61–75 years
and 75+. Five cases were obtained per group, except
for the 75+ group, where only three non-neurological
cases were available. Case details are provided in
Table 1. Haematoxylin and eosin (Cellpath, UK) stained
sections of human cortex were examined from each
case by a neuropathologist and immunohistochemistry
was carried out with antibodies to phospho-tau (AT8)
and b-amyloid to document age-associated pathological
changes in the tissue.
Evans blue assay
Evans blue (Sigma, UK), 2% in PBS at 80 mg/kg, was
administered intraperitoneally 24 h before mice from
each age group were anaesthetized with sodium
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pentobarbital and sacrificed (n = 6 per group). Intracar-
diac perfusion was then performed through the left
ventricle with 100 ml of 0.9% ice-cold saline using a
peristaltic pump (speed 7.5 ml/min) to remove
intravascular Evans blue. Blood was collected from the
right ventricle by cardiac puncture. Brain and spinal
cord were dissected, weighed and homogenized in PBS.
Then, 2.5 ml of trichloroacetic acid (Sigma, UK) was
added and samples were incubated on ice for 30 min
before centrifugation at 1000 g at 4°C for 30 min.
Absorbance of supernatants and plasma (dilution factor
100x) were measured at 610 nm. The results were
normalized to wet weight of tissue and plasma concen-
tration of Evans blue and expressed as (ml of plasma)/
(g of tissue).
Immunohistochemistry
Immunohistochemistry was performed using a standard
avidin–biotin complex–horse radish peroxidase
(ABC-HRP) method, and visualized with diaminoben-
zidine (Vector Laboratories, UK), except for albumin
immunohistochemistry which was performed using a
standard ABC–alkaline phosphatase method, and visual-
ized with alkaline phosphatase red substrate (Vector Lab-
oratories, UK). Both isotype controls and no primary
antibody controls were included in every run. A sum-
mary of all the primary antibodies and their conditions
of use is shown in Table 2. All immunohistological eval-
uation of both the human and mouse ageing cohorts
was performed blind to any clinical information.
Plasma proteins BBB leakage in human tissue was
determined using immunohistochemistry to plasma
proteins: albumin (67 kDa), fibrinogen (340 kDa) and
immunoglobulin G (IgG, 150 kDa). Staining patterns
were scored semiquantitatively in the area of most
intense immunoreactivity (920 objective) and
independently scored by a second observer to assess
interobserver variability. Assessment was based on
Table 1. Human brain bank cases demographics
Age
group Age Gender
Post mortem
interval (h) Cause of death Neuropathology
20–30 20 F 71 Suspension by ligature None
24 F 47 Suspension by ligature Small vessel disease/perivascular spaces and arteriosclerosis
25 M 53 Suspension by ligature None
29 M 44 Suspension by ligature Focal tau, no neuritic plaques
30 M 71 Unascertained None
31–45 32 F 63 Cardiomyopathy/Marfan’s
syndrome
None
36 M 41 IHD None
39 F 43 Suspension by ligature None
42 M 61 IHD None
44 M 47 Drug overdose None
46–60 46 M 52 IHD None
48 M 72 CAD None
50 M 45 IHD/CAD None
52 M 91 Road traffic collision None
57 M 66 IHD/CAD None
61–75 63 F 35 IHD/CAD Mild amyloid tangles and plaques
70 F 79 Ruptured aneurysm Large vessel arteriosclerosis and ischaemic white matter pathology.
Mild tau threads and tangles. Mild vascular amyloid, tangles
and plaques
71 F 41 IHD Mild and focal vascular tau. Mild amyloid tangles and plaques
74 M 46 Pulmonary thromboembolism None
74 M 66 IHD/CAD White matter pallor, mild tau tangles, plaques and treads.
Mild vascular amyloid, tangles and plaques
75+ 75 M 78 IHD/CAD Mild tau tangles and treads
76 M 90 CAD/Myocardial infarction Mild tau tangles and treads
79 F 45 IHD/CAD Venous collagenosis and small vessel disease
IHD, ischaemic heart disease; CAD, coronary artery disease.
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proportions of positive neurons, parenchymal/
perivascular staining and white matter staining, using
schemes modified from our previous studies in cortex
and white matter (illustrated in [21,22]). In the cortex,
neuronal immunoreactivity was assessed as none (1),
isolated (2), frequent, representing up to approximately
50% of neurons (3) or very frequent, representing
more than 50% (4). Parenchymal/perivascular
immunoreactivity was scored as none (1), patchy (2)
or confluent (3). In the white matter, serum protein
immunoreactivity was graded as follows: some blood
vessels displaying evidence of perivascular albumin
deposition (1), weak glial reactivity in addition to the
perivascular deposition (2), many positive glial cells
within the parenchyma (3) and intense, confluent
perivascular and parenchymal albumin reactivity with
many positive glia (4).
Tight junction proteins Immunohistochemistry to
zonula occludens-1 (ZO-1) was carried out to identify
breaks in tight junctions, using the primary–secondary
method, and visualized with Alexa Fluor 594-
conjugated secondary antibody. In the mouse tissue,
Z-stacks of 30 vessels were imaged from both the
cerebral cortex and cerebellum of each mouse, using
Zeiss confocal microscopy and analysed by Image J
software. In brief, the outline of individual vessels was
traced from deconvoluted Z-stack images and plot
profiles displayed as pixel distance against grey value.
Tight junction integrity was assessed by measuring
break length per 100 lm of microvessel, number of
breaks per 100 lm of microvessel and average break
length. The break was registered when the grey value
was lower than the threshold determined by using
mean of background  2 standard deviations in Image
J software.
NVU cells Assessment of specific immunoreactivity
was performed by capturing bright-field microscopic
images in three adjacent 350-lm-wide cortical ribbons,
consisting of contiguous fields to cover the total
cortical thickness, using a 920 objective (Nikon Eclipse
Ni-U microscope, Nikon, UK) and analysed using the
Analysis ^D software (Olympus Biosystems, Watford,
UK). To further assess microvascular changes in the
human cohort, microvascular density was assessed
using immunohistochemistry to CD31. Percentage
CD31 area immunoreactivity and intervessel pixel
distance were quantitated using Analysis D software.
Percentage area pericyte coverage of capillaries was
assessed in a subset of old (n = 6, aged over 70) and
young human cases (n = 5, aged 30 and below) using
double staining: periodic acid–Schiff (PAS) to stain
vessels and immunohistochemistry to PDGFRb to
specifically label pericytes. Astroglial and microglial
responses in perivascular regions and neuropil were
examined with immunohistochemistry to GFAP and
Iba1 respectively.
Statistical analysis
Statistical analyses were performed using IBM SPSS
Statistic v20 and GraphPad Prism v6. Spearman’s rank
correlation was used to assess the relationship between
Table 2. Antibody sources and experimental conditions
Antibody Tissue Isotype Dilution (time, temp) Antigen retrieval Supplier
Tau (AT8) Human FFPE Mouse IgG 1:400 (o/n, 4°C) MW 10 min, TSC pH 6.5 Endogen, UK
b-amyloid Human FFPE Mouse IgG 1:100 (o/n, 4°C) MW 10 min, TSC pH 6.5* DakoCytomation, UK
Albumin Human FFPE Rabbit IgG 1:15 000 (1 h, RT) MW 10 min, TSC pH 6.5 DakoCytomation, UK
Fibrinogen Human FFPE Rabbit IgG 1:3000 (1 h, RT) MW 10 min, TSC pH 6.5 DakoCytomation, UK
IgG Human FFPE Rabbit IgG 1:32 000 (1 h, RT) PC, EDTA pH 8 DakoCytomation, UK
CD31 Human FFPE Rabbit IgG 1:100 (1 h, RT) MW 10 min, TSC pH 6.5 AbCam, UK
GFAP Human FFPE Rabbit IgG 1:1000 (1 h, RT) MW 10 min, TSC pH 6.5 DakoCytomation, UK
IBA1 Human FFPE Mouse IgG 1:200 (1 h, RT) MW 10 min, TSC pH 6.5 Millipore, UK
ZO-1 Mouse frozen Rabbit IgG 1:100 (o/n, 4°C) N/A Invitrogen, UK
CD31 Mouse frozen Rat IgG 1:10 (o/n, 4°C) N/A BD Bioscience, BD Pharmingen
FFPE, formalin-fixed paraffin embedded; o/n, overnight; MW, microwave; TSC, trisodium citrate; RT, room temperature; PC, pressure coo-
ker; EDTA, ethylenediaminetetraacetic acid; N/A, not applicable.
*Antigen retrieval carried out following pretreatment with formic acid for 5 h.
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histoscores and age. Interobserver variability was
assessed using weighted kappa. Trend analyses for age
groups were performed using the Jonckheere–Terpstra
test (JT) unless otherwise stated. Evans blue and ZO-1
data were not normally distributed and did not show
equality of variances between groups, therefore analy-
ses were performed using nonparametric methods. The
relationship of these markers to age was determined
using Kruskal–Wallis test (KW), and the presence of
trends analysed using the JT test. Pericyte coverage
data were analysed using unpaired T test, following
confirmation of normal distribution of data via
Shapiro–Wilk test.
Results
Loss of ZO-1 expression is associated with ageing in
the mouse brain
To quantify BBB permeability across our aged cohort of
mice we used albumin-binding Evans blue dye assays.
Under normal conditions, with an intact BBB, the albu-
min–dye complex cannot enter the CNS; when the BBB
is disrupted, neighbouring tissues stain blue. Signifi-
cantly more Evans blue was detected in the cerebellum
compared to the cortex across all ages (P < 0.001)
(Table S1), suggesting regional differences in BBB per-
meability. However, within the cortex there was no sig-
nificant difference between age groups (KW P = 0.49)
and no trend to increased Evans blue extravasation
associated with age (JT P = 0.237) (Figure 1A). Simi-
larly, within the cerebellum there was no significant
difference between age groups (KW test P = 0.45) and
no trend to increased Evans blue extravasation
associated with age (JT P = 0.237) (Figure 1B). ZO-1
staining patterns revealed linear outlines of tight junc-
tions along microvessels (Figure 2A) with focal areas of
loss representing breaks in the BBB (Figure 2B). Within
the cortex and cerebellum quantification of the number
of breaks in the BBB showed a significant difference
between groups (KW: cortex P = 0.012, cerebellum
P = 0.025), with a significant trend to increased num-
ber of breaks associated with age (JT: cortex
P < 0.001, cerebellum P < 0.001) (Figure 2C,E).
Within the cortex and cerebellum quantification of BBB
break length showed a significant difference between
groups (KW: cortex P = 0.011, cerebellum P = 0.019),
with a significant trend to increased break length asso-
ciated with age (JT: cortex P < 0.001, cerebellum
P < 0.001) (Figure 2D,F).
Human case characterization across the ageing
cohort
Haematoxylin and eosin-stained sections demonstrated
some white matter pallor in five cases, all over
50 years of age. Diffuse and compact amyloid plaques,
with occasional amyloid in vessels were seen in four
cases (age 63–74 years) and vascular amyloid was
seen in two of these four cases. Mild tau pathology was
observed in four cases, all aged over 70 years of age.
These tau and amyloid pathologies are very commonly
seen in normal ageing [26,27]. One young case
(29 years) showed a single focus of tau pathology with-
out neuritic plaques (Figure S1) and a second case in
this youngest group showed some widening of perivas-
cular spaces and arteriolosclerosis, suggestive of mild
small vessel disease.
Figure 1. BBB permeability in mice. Quantification of Evans blue did not detect significant age-associated BBB changes in the (A) cortex
or (B) cerebellum of an ageing mouse cohort.
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Increased extrusion of serum proteins is associated
with ageing in the human brain
Quantification of tight junction breaks was not per-
formed in the human tissue. Although this method has
been successful in our hands in another human
autopsy cohort [21,22], we obtained only diffuse
endothelial staining in this human cohort, without the
clear pattern of intercellular junctions, suggesting arte-
factual degradation of these membrane-associated pro-
teins. Therefore, further analysis was not attempted
using tight junction markers in the human tissue.
Immunohistochemistry to three serum proteins (al-
bumin, fibrinogen and IgG) showed a variety of
staining patterns with variation between cases, as
shown in Figure 3. Both fibrinogen and IgG
immunopositive neurons were detected in the cortex
(Figure 3A,B). In white matter, perivascular and diffuse
staining patterns were seen (Figure 3C,D), with some
cases containing large, round immunopositive cells
morphologically recognizable as clasmatodendritic
astrocytes (Figure 3E,G). Staining of the subpial region
(layer 1) was widespread across the cohort with little
variation (therefore, layer 1 was not included in quan-
tification). Immunostaining of IgG in the white matter
showed a strong positive association with ageing (JT
test, P = 0.002) (Figure 3H), while neuronal and vas-
cular IgG scores did not correlate with ageing. The
(A)
(C) (D)
(E) (F)
(B)
Figure 2. Age-associated loss of ZO-1 in mice. (A) ZO-1 immunolabelling of tight junctions in a young mouse (3 months). (B) Breaks in
endothelial ZO-1 expression were quantitated in the ageing mouse cohort, as indicated by the white arrows (24 month case). A
significant trend to increased (C) number (P < 0.001) and (D) length (P < 0.001) of tight junction protein breaks associated with age in
the cortex. A significant age-associated increase in (E) the number (P < 0.001) and (F) length (P < 0.001) of tight junction protein
breaks were also detected in the cerebellum. Scale bar represents 5 lm in A and B.
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score of the first observer was used for analysis, with
the score of the second observer used to check interob-
server variation in scoring. Neuronal IgG staining
showed moderate agreement between scorers
(j = 0.491), vascular and white matter scoring showed
low agreement between scorers (j = 0.169 and
j = 0.152 respectively), suggesting that these patterns
are harder to assess, with consequently less
(A)
(C)
(E)
(G)
(B)
(D)
(F)
(H)
Figure 3. Serum protein accumulation in the ageing brain. (A) Fibrinogen and (B) IgG immunopositive neurons. (C) Fibrinogen and (D)
IgG perivascular immunostaining. (E) Fibrinogen, (F) IgG and (G) albumin clasmatodendritic astrocytes were observed in the ageing
human cohort. (H) IgG immunoreactivity in the white matter positively associated with age (P = 0.002). Scale bar represents 100 lm in
A,E,G; 50 lm in B,C,F and 200 lm in D.
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interobserver reliability. The mean white matter IgG
score of the two observers also showed an increase
with age (JT P = 0.004). Initial analysis of fibrinogen
did not reveal a significant relationship with age. How-
ever, we noticed a trend towards fibrinogen increase
with age, except in the youngest group, where fibrino-
gen scores were also high. This group (Table 1) had
mostly died by suspension ligature, raising the question
of whether perimortem raised venous pressure might
have contributed to higher leakage at this age. In addi-
tion, we observed unusual pathology in two of the
cases within this group, specifically, a focal region of
tau immunoreactivity (Figure S1) and white matter
pathology. We therefore repeated the analysis, exclud-
ing the youngest age group. Fibrinogen now also
showed an age relationship in both the grey
(P = 0.011) and white matter (P = 0.044). Albumin,
with the lowest molecular weight, showed more exten-
sive distribution in the human tissue and no correla-
tion with increasing age. We examined the relationship
of fibrinogen and IgG leakage to post mortem delay in
our cohort and did not find a significant correlation
(data not shown).
Age-associated changes in glial pathology
GFAP+ astrocytes with a classic stellate morphology
were detected in the mouse cohort (Figure 4A). Levels
of GFAP expression, assessed as percentage area
immunoreactivity, showed a significant increase in the
mice with ageing (KW P = 0.037) (Figure 4B). A JT
trend test on these data was not significant. However,
the plots show that GFAP is higher at 3 months, then
drops before increasing steadily with age. If the
3-month group is excluded, then the JT test showed a
significant increase with age (P = 0.016). GFAP expres-
sion was also examined in the human ageing cohort
(Figure 4C). No increase in GFAP percentage reactivity
with age was observed in the human tissue samples;
however, a variety of staining patterns were observed.
We therefore used semiquantitative analysis to assess
for gliosis alone and observed a significant increase
with age in humans (JT P = 0.003) (Figure 4D). Nota-
bly, gliosis was a prominent feature in the over
60 years old cases, but we did not detect increasing
perivascular gliosis with ageing. Iba-1+ microglia were
also examined in the human cohort (Figure 4E). The
percentage area immunoreactivity of Iba-1 did not
increase with ageing and perivascular microgliosis was
not detected (Figure 4F).
No age-associated changes in microvascular density
or pericyte coverage
No changes in the pattern of immunostaining of the
endothelial marker CD31 (either area immunoreactivity
for CD31 or numbers of vessels) or intervascular pixel
distance were observed in the human tissue (Fig-
ure 5A,B). Pericyte coverage of vessels was compared
in young (mean age = 26.7 years) vs. old (mean
age = 74.8 years) subcohorts. There was no significant
difference in percentage pericyte coverage between the
two groups (P = 0.97, 10df, mean difference 0.34%,
95% CI: 23.4 to 22.72) (Figure 5C,D).
Discussion
In the current study, we present evidence of microvas-
cular changes associated with normal ageing in both
mouse and human cohorts. Evans blue extravasation
in the mouse cohort was significantly higher in the
cerebellum than the cortex across all ages. The finding
of regional differences supports morphometric evidence
for age-associated regional variation, suggesting certain
brain areas are more susceptible to BBB breakdown
than others [28,29]. These variations may contribute
to the inconsistent outcomes of BBB permeability stud-
ies carried out in ageing to date [20]. Changes in the
expression of the tight junction protein ZO-1 are closely
associated with the degree of BBB damage [30]. Using
more rigorous quantitative analysis of the tight junc-
tion protein ZO-1, we demonstrate a highly significant
increase in BBB breaks throughout the life of our
mouse cohort. As the loss of ZO-1 gradually accumu-
lated over time and occurred at earlier time points, this
suggests a physical disruption to tight junctions and
the resulting increased paracellular flux is a contributor
to the consequent leakage. ZO-1 protein levels are
dynamic and respond to physiological and pathological
conditions, such as hypoxia, oxidative stress and
inflammation, which are features of normal ageing and
could potentially be driving BBB leakage [31–33].
We also observed a gradual age-associated increase
in astroglial activation in the mouse cohort. These
changes preceded events that we may consider as
pathological, such as BBB leakage, which occurred at
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old age in the mice. GFAP levels were also higher in 3-
month-old mice, supporting a role for the protein dur-
ing development [34]. These findings highlight the
importance of looking longitudinally to understand
brain ageing and find intervention targets.
Although immunohistochemical detection of ZO-1
has been successful in other human autopsy cohorts
[21,22,35], in the current study only diffuse endothe-
lial staining was observed with no clean signal along
endothelial cell boundaries, suggesting artefactual
degradation. Therefore, immunohistochemistry to
serum proteins was employed to assess BBB leakage in
the ageing human brain. In contrast to the mouse
cohort, cortical changes were less clear in our human
cohort and there was considerable population varia-
tion. Increased fibrinogen extravasation positively asso-
ciated with age in all but the youngest. In this
youngest age group, 4/5 died by suspension, suggesting
that raised venous pressure perimortem might have dri-
ven serum protein accumulation. This group also
showed other minor pathological features, gliosis and
some focal tau in one case, the significance of this is
(A)
(C)
(E)
(B)
(D)
(F)
Figure 4. Age-associated changes in glial pathology. (A) GFAP immunolabelling of astrocytes in the mouse brain. (B) GFAP area
immunoreactivity correlates with age in all but the youngest age group of the mouse cohort (P = 0.016). (C) GFAP immunolabelling of
astrocytes in the human brain. (D) In the ageing human cohort, semiquantitative assessment of gliosis in the cortex expression
demonstrates an association with age (P = 0.003). (E) Iba-1+ microglia in the human brain. (F) In contrast to GFAP, no age-associated
changes in Iba-1 expression were detected. Scale bar represents 50 lm in A,C,E.
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uncertain as these cases had no neurological disease
but may suggest subtle brain abnormalities in this
group.
Although the majority of ageing research is focussed
on cortical pathology, white matter vascular changes
have also been detected by imaging [36,37] and shown
to contribute to cognitive decline in the ageing popula-
tion, as recently reviewed [38]. In the current study, we
demonstrate increased vascular leakage in the ageing
white matter, particularly IgG, accompanied by the pres-
ence of clasmatodendritic astrocytes. These serum pro-
tein-positive astrocytes have a swollen, rounded form
with loss or fragmentation of processes and are consid-
ered to reflect BBB leakage in white matter [39,40]. A
consequence of clasmatodendrosis is a decrease in astro-
cyte end-feet coverage of blood vessels which could com-
promise the neurovascular unit and was recently shown
to associate with cognitive decline following stroke [41].
Breakdown of the BBB leads to accumulation of cir-
culatory molecules (such as inflammatory molecules
and serum proteins) within the brain. The observed
uptake of serum proteins in neuronal cell bodies and
glia within our cohort support this, and such molecules
may stimulate a neuroinflammatory response [42]. We
demonstrate an increase in gliosis associated with age-
ing, in keeping with the changes in GFAP expression
observed in the mouse cohort. We did not observe a
change in the number or morphology of perivascular
microglia, however, future studies are required to
assess levels of microglial activation, for example, MHC
II expression.
There have been several vascular density studies in
ageing (reviewed in detail in Ref. [43]) and overall
results have been mixed with regional differences and
variable results in neurodegeneration. In the current
study, microvascular density was not affected by nor-
mal ageing in the brain regions studied. Previous stud-
ies have found evidence of pericyte loss with ageing
associated with BBB breakdown [44]. Although we did
observe loss of pericyte coverage in the human cohort,
there was no correlation with age. However, we exam-
ined relatively few cases and, given the wide confidence
intervals for percentage pericyte coverage, a larger
study is required.
(A)
(C)
(B)
(D)
Figure 5. Age-associated changes in vascular pathology. (A) CD31 immunolabelling of cerebral vessels in the human cortex. (B) No
significant age-associated changes in microvascular density were detected. (C) PCGFRb+ pericytes (brown) are intimately associated with
vessels (PAS, red). (D) There was no significant difference in the pericyte coverage of vessels in the youngest vs. the oldest group. Scale
bar represents 50 lm.
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A limitation of any study using human autopsy
material is post mortem sampling, with results difficult
to interpret as they can be affected by agonal events,
population variation, coexisting pathology and post
mortem uptake of serum proteins. The current study
selected non-neurological cases, but causes of sudden
death varied between age groups, which may be most
relevant in the youngest group, and subclinical age-
related pathology may vary. Thus, pathological exami-
nation revealed some instances of white matter pallor
and tau pathology as expected in an ageing brain. Post
mortem leakage of serum proteins may also occur from
delay in autopsy [45], although we did not find a rela-
tionship with post mortem delay in our cohort. Because
of the difficulties in examining BBB changes in human
autopsy tissue, we carried out parallel studies in mice.
The comparability of findings provides further evidence
that this is a process generally relevant to brain ageing,
and that the mouse is a good model to study age-
related BBB and NVU changes.
Overall this study provides evidence for BBB dysfunc-
tion in the normal brain ageing process and indicates
importance for both white matter and cortex. Collec-
tively, our data suggests that disruption to the BBB
may initiate processes contributing to declining func-
tion. Changes in some of the cellular and molecular
components of the BBB and NVU appear to develop
progressively with ageing. More accurate measures of
BBB integrity could therefore be a biomarker that pre-
dicts poorer brain ageing and therefore increased risk
of cognitive decline. Defining processes related to the
BBB and NVU may yield predictive and intervention
targets that may be of value in mid-life as well as at
older ages as part of efforts to improve healthy brain
ageing.
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